pharma

Heart Drug Spotlights Troubling Trends In Drug Marketing

A company is marketing a drug intended as a preventive for people at risk for heart disease with stunning statistics but has not yet released details of its study.

At the end of September, Amarin Corp. teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease. The claim was astounding: a 25 percent relative risk reduction for deaths related to heart attacks, strokes and other conditions.

Pharma Showers Key Oregon Lawmakers With Money

This article is for premium subscribers. Please sign up here for a tax-deductible subscription. 

If you're a premium subscriber, sign in below. 

The industry has given big bucks to U.S. Rep. Greg Walden, who chairs a powerful congressional committee, but has ignored Rep. Peter DeFazio, who is not on any committees that influence drug legislation.

Oregon’s congressional delegation includes members who are among the most courted by the nation’s pharmaceutical industry, and those who are among the most shunned, a new study shows, as the battle over sky-high U.S. prescription drug prices takes on a greater intensity.

Congress Bans Pharmacist ‘Gag Orders’ On Drug Prices

Pharmacists have been prevented from telling consumers when the cash price for a drug is lower than the cost through their insurer. But critics say this will not affect the causes of high drug prices.

For years, most pharmacists couldn’t give customers even a clue about an easy way to save money on prescription drugs. But the restraints are coming off.

Pages

Subscribe to pharma